Stock Analiz

Usana Health Sciences Inc. USNA

Medicinal Chemicals and Botanical Products · data as of November 13, 2026

$13.24Market cap $245M
Open the interactive analysis →

Usana Health Sciences Inc. (USNA) is a healthcare company listed in the US with a market value of about $245M. In the twelve months to October 3, 2026 it had revenue of $906M and net income of -$21M, a net margin of -2.3%.

Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is future growth (0/5).

Key numbers: a price to free cash flow of 8.3, 5-year revenue growth of -4% a year, a 5-year average ROIC of 13%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 96% above the current price.

About Usana Health Sciences

Usana Health Sciences is listed in the US and classified in medicinal chemicals and botanical products. Revenue went from $790M in 2014 to $925M in 2025, growth of about 1.4% a year. It was profitable in 10 of the last 10 years in our data. Its share count fell by 4% over three years (buybacks). It spends 1% of revenue on research and development.

Score: 2.4 / 5

Value2/5
Future growth0/5
Track record2/5
Financial health5/5
Shareholder returns3/5

Checks passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E13.4
P/FCF8.3
P/S0.3
P/B0.5
EV/EBITDA3.4
PEG—
Dividend yield0.00%
FCF yield12.1%
Shareholder yield11.2%
Intrinsic value vs. price+96%

Growth and quality

Revenue growth (1 yr)8.3%
Revenue growth (5 yrs, per year)-4.0%
EPS growth (5 yrs, per year)-37.0%
FCF growth (3 yrs, per year)-55.0%
Net margin (5-yr avg.)5.9%
ROIC (5-yr avg.)13.3%
Profitable years (of last 10)10
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$906M$925M$855M$921M$999M$1.2B$1.1B$1.1B$1.2B$1.0B$1.0B
Net income-$21M$11M$42M$64M$69M$117M$125M$101M$126M$63M$100M
Free cash flow$30M$9M$51M$56M$94M$108M$145M$110M$141M$111M$104M
EPS (diluted)$-1.14$0.58$2.19$3.30$3.59$5.73$5.86$4.41$5.12$2.53$3.99
Net margin-2.3%1.2%4.9%6.9%6.9%9.8%11.0%9.5%10.6%6.0%9.9%
ROIC—5.2%6.4%11.3%15.3%28.2%27.5%25.9%31.7%28.8%30.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $22.00, 66% above the current price; targets range from $22.00 to $22.00; the consensus rating is “Strong buy”; expected EPS is $0.55 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Usana Health Sciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 96% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Usana Health Sciences pay a dividend?

Not currently.

Is Usana Health Sciences a good stock to buy?

We do not give buy or sell advice. Usana Health Sciences scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.